Jan 6, 2026 06:29AM Adicet Bio Inc. (ACET) PT Lowered to $18 at Canaccord Genuity

Nov 19, 2025 04:15AM Adicet Bio (ACET) is Fairly Valued - Citizens

Nov 5, 2025 04:02PM ACETO Corp (ACET) Tops Q3 EPS by 1c

Oct 8, 2025 08:05AM Adicet (ACET) Bio lupus trial data promising, says Citizens JMP

Oct 7, 2025 12:45PM Adicet Bio Inc. (ACET) PT Raised to $8 at Guggenheim

Sep 9, 2025 04:10AM Citizens JMP Reiterates Market Perform Rating on Adicet Bio Inc. (ACET)

Aug 13, 2025 04:11AM Citizens JMP Reiterates Market Perform Rating on Adicet Bio Inc. (ACET)

Jul 23, 2025 07:46AM H.C. Wainwright Assumes Adicet Bio Inc. (ACET) at Buy

May 30, 2025 05:01AM Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025

May 6, 2025 05:43PM ACETO Corp (ACET) Tops Q1 EPS by 2c

Apr 21, 2025 04:20AM Citizens JMP Reiterates Market Perform Rating on Adicet Bio Inc. (ACET)

Apr 17, 2025 07:01AM Adicet Bio (ACET) Appoints Michael Grissinger to the Board of Directors

Mar 7, 2025 06:47AM H.C. Wainwright Reiterates Neutral Rating on Adicet Bio Inc. (ACET)

Mar 6, 2025 05:20PM ACETO Corp (ACET) Tops Q4 EPS by 3c

Mar 6, 2025 05:01PM Adicet Bio (ACET) Files $250M Mixed Shelf

Feb 27, 2025 07:02AM Adicet Bio (ACET) Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis

Feb 5, 2025 07:10AM Adicet Bio (ACET) Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Jan 8, 2025 04:10PM Adicet Bio (ACET) Provides Corporate Update and Highlights Expected 2025 Milestones

Dec 19, 2024 07:03AM Adicet Bio (ACET) Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Dec 18, 2024 07:00AM Adicet Bio (ACET) Appoints Julie Maltzman as Chief Medical Officer

Nov 18, 2024 04:00PM Adicet Bio (ACET) Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Nov 18, 2024 07:09AM Adicet Bio (ACET) Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Nov 7, 2024 06:14AM Guggenheim Reiterates Buy Rating on Adicet Bio Inc. (ACET)

Nov 6, 2024 04:00PM ACETO Corp (ACET) Reports In-Line Q3 EPS

Oct 17, 2024 06:56AM H.C. Wainwright Reiterates Neutral Rating on Adicet Bio Inc. (ACET)

Oct 16, 2024 07:01AM Adicet Bio (ACET) Announces FDA Clearance of IND Amendment for ADI-001

Oct 1, 2024 07:04AM H.C. Wainwright Reiterates Neutral Rating on Adicet Bio Inc. (ACET)

Sep 30, 2024 06:44AM Guggenheim Starts Adicet Bio Inc. (ACET) at Buy

Sep 20, 2024 06:51AM H.C. Wainwright Reiterates Neutral Rating on Adicet Bio Inc. (ACET)

Sep 19, 2024 07:02AM Adicet Bio (ACET): ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue

Sep 11, 2024 06:58AM Adicet Bio Inc. (ACET) PT Lowered to $8 at Canaccord Genuity

Sep 10, 2024 04:29PM Adicet Bio Inc. (ACET) PT Lowered to $4 at Jones Trading

Aug 19, 2024 07:01AM Adicet Bio (ACET) Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

Aug 14, 2024 06:11AM BTIG Reiterates Buy Rating on Adicet Bio Inc. (ACET)

Aug 13, 2024 07:44AM ACETO Corp (ACET) Tops Q2 EPS by 3c

Jul 8, 2024 07:02AM Adicet Bio (ACET) Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Jun 24, 2024 07:03AM Adicet Bio (ACET) Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma